Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND & AIMS">Genetic factors associated with non-alcoholic fatty liver disease (NAFLD) remain incompletely understood. To date, most genome-wide association studies (GWASs) have adopted radiologically assessed hepatic triglyceride content as the reference phenotype and so cannot address steatohepatitis or fibrosis. We describe a GWAS encompassing the full spectrum of histologically characterised NAFLD.</AbstractText>METHODS: <AbstractText Label="METHODS">The GWAS involved 1,483 European NAFLD cases and 17,781 genetically matched controls. A replication cohort of 559 NAFLD cases and 945 controls was genotyped to confirm signals showing genome-wide or close to genome-wide significance.</AbstractText>RESULTS: <AbstractText Label="RESULTS">Case-control analysis identified signals showing p values ≤5 × 10-8 at 4 locations (chromosome [chr] 2 GCKR/C2ORF16; chr4 HSD17B13; chr19 TM6SF2; chr22 PNPLA3) together with 2 other signals with p <1 × 10-7 (chr1 near LEPR and chr8 near IDO2/TC1). Case-only analysis of quantitative traits showed that the PNPLA3 signal (rs738409) had genome-wide significance for steatosis, fibrosis and NAFLD activity score and a new signal (PYGO1 rs62021874) had close to genome-wide significance for steatosis (p = 8.2 × 10-8). Subgroup case-control analysis for NASH confirmed the PNPLA3 signal. The chr1 LEPR single nucleotide polymorphism also showed genome-wide significance for this phenotype. Considering the subgroup with advanced fibrosis (≥F3), the signals on chr2, chr19 and chr22 maintained their genome-wide significance. Except for GCKR/C2ORF16, the genome-wide significance signals were replicated.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS">This study confirms PNPLA3 as a risk factor for the full histological spectrum of NAFLD at genome-wide significance levels, with important contributions from TM6SF2 and HSD17B13. PYGO1 is a novel steatosis modifier, suggesting that Wnt signalling pathways may be relevant in NAFLD pathogenesis.</AbstractText>LAY SUMMARY: <AbstractText Label="LAY SUMMARY">Non-alcoholic fatty liver disease is a common disease where excessive fat accumulates in the liver and may result in cirrhosis. To understand who is at risk of developing this disease and suffering liver damage, we undertook a genetic study to compare the genetic profiles of people suffering from fatty liver disease with genetic profiles seen in the general population. We found that particular sequences in 4 different areas of the human genome were seen at different frequencies in the fatty liver disease cases. These sequences may help predict an individual's risk of developing advanced disease. Some genes where these sequences are located may also be good targets for future drug treatments.</AbstractText>

The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement

Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice

Consensus on the Diagnosis and Treatment of Cholestatic Liver Diseases (2015, China)

Asian Pacific Association for the Study of the Liver Consensus Statements on the Diagnosis, Management and Treatment of Hepatitis C Virus Infection

Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities

Validation of a hierarchical algorithm to define chronic liver disease and cirrhosis etiology in administrative healthcare data

Paediatric steatotic liver disease has unique characteristics: A multisociety statement endorsing the new nomenclature

A global action agenda for turning the tide on fatty liver disease

Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction

Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature

The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease

S1778 Current Recommendations on Etiological Testing in Liver Cirrhosis: Is It Time for a Stepwise Approach?

Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensus

From non-alcoholic fatty liver disease to metabolic-associated steatotic liver disease: Rationale and implications for the new terminology

Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management

Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline

Validating new coding algorithms to improve identification of alcohol-associated and nonalcohol-associated cirrhosis hospitalizations in administrative databases

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆

Navigating The 2022 International Consensus and World Health Organization Classifications of Hematopathology: A Call for Unified Diagnostic Language